For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...